Ki sa "Klè" vle di?
Bèt la pa pote mitasyon an. Li pa pral devlope maladi a epi yo pa pral pase li sou.
Chen Miopati santnikleyè nan Labrador Variant 2 (CNM-L2)
The Centronuclear Myopathy In Labrador Variant 2 (CNM) DNA test is essential for responsible Labrador owners and breeders. This genetic test detects the presence of the CNM mutation, a hereditary muscle disorder affecting Labradors. Early identification through DNA testing helps prevent the breeding of affected dogs, promoting healthier litters. CNM causes muscle weakness and mobility issues, impacting a dog’s quality of life. By using the CNM DNA test, breeders can make informed decisions to reduce the incidence of this condition. Regular testing supports the overall health and longevity of Labrador Retrievers. Ensure your Labrador’s well-being with accurate CNM genetic screening today.
Abreviyasyon: CNM-L2
Analize mitasyon: HACD1 insCACACAAAGGTTT]
Eritaj: Otozomal resesif
Akwonim
CNM-L2
Obsève frekans
Gravite nan klinik
Klasifikasyon klinik
Maladi miskilè
Analize mitasyon
HACD1 insCACACAAAGGTTT]
Mòd eritaj
Otozomal resesif
Rezime tès la:
The Centronuclear Myopathy In Labrador Variant 2 (CNM) DNA test detects a genetic mutation responsible for a muscle disorder in Labrador Retrievers. This condition causes muscle weakness and difficulty with movement, often appearing in young dogs. Early identification through testing helps breeders avoid passing the mutation to offspring. Responsible breeding practices reduce the incidence of CNM and improve the overall health of the breed. DNA testing is a valuable tool for maintaining the well-being of Labradors.
Disponib nan pake a: Basic
Tès ADN sa a enkli apati pake nou an Basic — epi tou se yon pati nan pake yo Basic, Standard, Advanced, Complete.
Gade pake tès ADN →Chwazi pake ki pi byen adapte elvaj ou oswa estrateji sante bèt ou yo.
Understanding Centronuclear Myopathy in Labrador Variant 2 (CNM)
Centronuclear Myopathy in Labrador Variant 2 (CNM) is a genetic condition that primarily affects the muscle function in dogs, particularly in the Labrador Retriever breed. This myopathy is characterized by the presence of abnormal muscle fibers, which lead to muscle weakness and reduced mobility. The condition is caused by mutations in specific genes that are crucial for muscle development and maintenance.
Clinical Signs of CNM
The clinical signs of CNM typically appear in young dogs, often manifesting between six months and two years of age. Affected dogs may exhibit symptoms such as muscle weakness, difficulty in rising, exercise intolerance, and a tendency to become easily fatigued. Additionally, they may have a characteristic dropped posture due to weakness in the muscles of the hind limbs. The severity of symptoms can vary significantly among affected individuals.
Pathophysiology of CNM
At the cellular level, CNM is associated with abnormalities in the structure and function of muscle cells. The condition leads to the accumulation of centronuclear myopathy, where the nuclei of muscle fibers are located in the center rather than at the periphery. This abnormal positioning can impair normal muscle function and regeneration, ultimately resulting in progressive muscle weakness over time.
Diagnosis of CNM
Diagnosing Centronuclear Myopathy involves a combination of clinical evaluation and genetic testing. Veterinarians typically assess the dog’s medical history and perform a thorough physical examination. Muscle biopsies may also be conducted to observe the characteristic changes in muscle fibers. However, the definitive diagnosis is made through genetic testing that identifies the specific mutations associated with CNM.
Treatment and Management
Currently, there is no cure for Centronuclear Myopathy, and treatment options are primarily focused on managing symptoms and improving the quality of life for affected dogs. Supportive care, including physical therapy and weight management, can help maintain muscle function and mobility. Additionally, regular veterinary check-ups are essential for monitoring the condition and addressing any complications that may arise.
Enpòtans nan tès jenetik
Genetic testing plays a vital role in the management of CNM, particularly for breeding decisions. By identifying carriers of the CNM mutation, breeders can make informed choices to reduce the risk of producing affected offspring. This proactive approach is crucial for controlling the prevalence of this condition in the population and promoting the overall health of the breed.
Konklizyon
Centronuclear Myopathy in Labrador Variant 2 is a significant genetic disorder that impacts muscle function in dogs. Understanding the condition, its symptoms, and the importance of genetic testing can aid in better management and care for affected animals. Ongoing research and advancements in veterinary genetics continue to enhance our understanding of CNM, paving the way for potential future therapies and improved outcomes for affected dogs.
Race rekonèt pou tès la: Miopati santnikleyè nan Labrador Variant 2 (CNM-L2)
- Australian Cobberdog
- Golden Retriever
- Lab/Golden Cross
- Labradoodle
- Labrador Retriever
- UK Breed Council Labrador Retriever
🧬 Interpretation of genotypes CNM-L2
Jenotip
Estati
🟡 N/N
Ki pa konpayi asirans - Pa gen risk
🟡 N/CNM-L2
Konpayi asirans - Pa gen risk
❌ CNM-L2/CNM-L2
Afekte - Nan Risk
FAQ: konprann entèpretasyon an
Èske yon "Carrier" serye?
Non. Bèt la jeneralman an sante men li ka transmèt mitasyon an bay li pitit pitit.
E si yon bèt "Afekte"?
Li pote de kopi mitasyon. Siy klinik yo espere depann sou maladi a. Li pa ta dwe elve.
Poukisa gen diferans ant gason / fi?
Gen kèk maladi ki lye ak sèks, kidonk ekspresyon yo varye selon la sèks bèt.
Predi pitit pitit
N/N (ki-pa-transpote)
N/CNM-L2 (Carrier)
CNM-L2/CNM-L2 (Afekte)
FAQ Tès ADN
Kisa tès ADN sa a detekte?
This DNA test detects the mutation associated with Centronuclear Myopathy In Labrador Variant 2 (CNM-L2) in order to identify clear, carrier, or at-risk animals.
Poukisa teste yon bèt elvaj?
Tès ADN ede elve yo planifye kwazman ki pi an sekirite epi redwi risk pou yo transmèt mitasyon an bay pitit pitit yo.
Ki mòd eritaj tès sa a?
Mòd eritaj ki rapòte pou tès sa a se otozomal resesif.
Ki mitasyon ki analize nan tès sa a?
This test analyses the mutation HACD1 insCACACAAAGGTTT].
Èske yon bèt transporteur nesesèman afekte?
Pa nesesèman. Entèpretasyon depann sou modèl eritaj la ak jenotip ki kapab lakòz.
Referans
Pelé Manuel, Tiret Laurent, Kessler JeanLouis, Blot Stéphane, Panthier JeanJacques. SINE exonic insertion in the PTPLA gene leads to multiple splicing defects and segregates with the autosomal recessive centronuclear myopathy in dogs. Hum Mol Genet. 2005 Jun 1;14(11):1417-27. doi: 10.1093/hmg/ddi151. Epub 2005 Apr 13.